[Mirvetuximab soravtansin (ovarian cancer) – assessment in accordance with §35a (1) Sentence 11 Social Code Book (SGB) V]

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018014003
German
Original Title: Mirvetuximab-Soravtansin (Ovarialkarzinom)
Details
Project Status: Completed
URL for project: https://www.iqwig.de/projekte/g24-36.html
Year Published: 2025
URL for published report: https://www.iqwig.de/download/g24-36_mirvetuximab-soravtansin_bewertung-35a-absatz-1-satz-11-sgb-v_v1-0.pdf
English language abstract: There is no English language summary available
Publication Type: Full HTA
Country: Germany
DOI: https://doi.org/10.60584/G24-36
MeSH Terms
  • Ovarian Neoplasms
  • Fallopian Tube Neoplasms
  • Peritoneal Neoplasms
  • Maytansine
  • Immunoconjugates
  • Antibodies, Monoclonal, Humanized
Keywords
  • Mirvetuximab Soravtansine
  • Ovarian Neoplasms
  • Fallopian Tube Neoplasms
  • Peritoneal Neoplasms
  • Health Care Costs
  • Epidemiology
Contact
Organisation Name: Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address: IQWiG, Siegburger Str. 237, 50679 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email: berichte@iqwig.de
Copyright: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.